These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26021697)

  • 1. Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.
    Stukova M; Hall MD; Tsotsoros SD; Madigan JP; Farrell NP; Gottesman MM
    J Inorg Biochem; 2015 Aug; 149():45-8. PubMed ID: 26021697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
    Stronach EA; Alfraidi A; Rama N; Datler C; Studd JB; Agarwal R; Guney TG; Gourley C; Hennessy BT; Mills GB; Mai A; Brown R; Dina R; Gabra H
    Cancer Res; 2011 Jul; 71(13):4412-22. PubMed ID: 21571862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
    Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).
    Burger H; Zoumaro-Djayoon A; Boersma AW; Helleman J; Berns EM; Mathijssen RH; Loos WJ; Wiemer EA
    Br J Pharmacol; 2010 Feb; 159(4):898-908. PubMed ID: 20067471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
    Sakai W; Swisher EM; Jacquemont C; Chandramohan KV; Couch FJ; Langdon SP; Wurz K; Higgins J; Villegas E; Taniguchi T
    Cancer Res; 2009 Aug; 69(16):6381-6. PubMed ID: 19654294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
    Bhatt M; Ivan C; Xie X; Siddik ZH
    Oncotarget; 2017 Feb; 8(7):10905-10918. PubMed ID: 28038466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
    Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
    Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
    Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
    Sharp SY; Smith V; Hobbs S; Kelland LR
    Br J Cancer; 1998 Jul; 78(2):175-80. PubMed ID: 9683290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
    Sun X; Lou LG; Sui DH; Wu XH
    Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
    Cooke SL; Ng CK; Melnyk N; Garcia MJ; Hardcastle T; Temple J; Langdon S; Huntsman D; Brenton JD
    Oncogene; 2010 Sep; 29(35):4905-13. PubMed ID: 20581869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
    Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
    Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
    Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
    Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
    Ekblad L; Kjellström J; Johnsson A
    Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
    BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.